Endogenous bioactive lipids are part of a complex network that modulates a plethora of
cellular and molecular processes involved in health and disease, of which inflammation …

The future of next generation therapeutics for glaucoma is strong. The recent approval of two
novel intraocular pressure (IOP)-lowering drugs with distinct mechanisms of action is the first …

BACKGROUND Glaucoma is a group of diseases characterized by a specific pattern of optic
nerve neuropathy and retinopathy. Increasing evidence demonstrates glaucoma associated …

The combination of a β-adrenergic receptors (AR) blocker and a carbonic anhydrase (CA,
EC 4.2. 1.1) inhibitor in eye drops formulations is one of the most clinically used treatment for …

The management of patients with type 2 diabetes mellitus (T2DM) is shifting from cardio-
centric to weight-centric or, even better, adipose-centric treatments. Considering the …

Introduction: Glaucoma is a neurodegenerative disease of the eye characterized by
selective retinal ganglion cell loss that provokes progressive defects in the visual field …

Purpose: Δ 9-Tetrahydrocannabinol-valine-hemisuccinate, a hydrophilic prodrug of Δ 9-
tetrahydrocannabinol, synthesized with the aim of improving the ocular bioavailability of the …

Background: Glaucoma is a group of chronic diseases that cause progressive damage to the
optic nerve, resulting in irreversible and potentially debilitating visual loss. A unified …

ABSTRACT Introduction Fixed dose combinations (FCs) represent a potentially valuable
treatment strategy in glaucoma management. Fixed combinations not only improve …

Surprisingly, a very few studies on glaucoma medication or surgery addressed the concept
of adherence. However, adherence is discussed in studies which consider psychological …